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previous pamidronate treatment (45.8%). were identiﬁed. CON-
CLUSIONS: Although regression coefﬁcients are different, these
risk factors proved signiﬁcant in both multivariate models,
further supporting that these factors are likely important in pre-
dicting the renal impairment associated with ZA use in.
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OBJECTIVES: Generation of population cost estimates for
event-censored data requires a sophisticated approach to account
for probability of incurring the event over time and different
patient characteristics. We investigated Medicare costs speciﬁ-
cally associated with all-cause graft failure following kidney
transplantation. We were particularly interested in developing
methods to study cost and see how these methods can inform
decision makers. METHODS: A modiﬁed two-part econometric
approach was used to determine Medicare claims attributable to
all-cause graft failure (including deaths). The approach was
accomplished in 3 steps: 1) Time was partitioned into discrete
intervals whereby intervals were chosen to reﬂect changes in the
relationship between cost and patient characteristics. Within
each interval, we established the predictive relationship of the
log-transformed costs with relevant factors based on those
patients whose graft failed in the interval; 2) Probability of graft
failure at the end of each interval was estimated using Cox
hazards regression; and 3) Results of steps 1 and 2 were com-
bined mathematically to obtain population-based estimate of
cost. Data on adult, primary transplants from cadaveric donors
between 1993 and 1998 were obtained from the United States
Renal Data System. Covariates modeled included donor and
recipient characteristics, and clinical variables including
immunosuppression therapies. Costs among different risk groups
were compared to evaluate their relative impact. RESULTS:
Expected Medicare claims attributed to all-cause graft failure at
3-years post-transplant was highest among patients who experi-
enced acute rejection by 6-months post transplant (AR: $62,749
vs. No AR: $47,787). CCONCLUSIONS: For event-censored
data, the estimation of cost associated with an event requires a
sophisticated approach. The modiﬁed two-part model may
provide more reliable estimates but the validity of this procedure
requires further research. Speciﬁc to transplantation, these esti-
mates may provide groundwork for further studies to address
the potential cost-effectiveness of various treatments to delay or
prevent graft failure.
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OBJECTIVES: Modeling approaches are used to estimate future
consequences and costs of diabetes and its complications, since
few studies provide data over a sufﬁcient duration or for all
costs, effects and populations. The Diabetes Mellitus Model
(DMM) predicts 10-year outcomes for patients with Type 1
(T1DM) and Type 2 (T2DM) diabetes based on published clin-
ical trials; these predictions mirror clinical trial outcomes. We
compared the DMM against real world, population-based epi-
demiological data from the Diabetes Audit and Research in
Tayside Scotland (DARTS) database. METHODS: We studied
two cohorts of 931 T1DM (46% male) and 12,907 T2DM (53%
male) patients, mean (±SD) age at diagnosis 21 (±14) and 61
(±13) years, respectively. Mean A1c for DARTS patients, diag-
nosed from 1 January 1993 to 31 December 2000, was derived
as a function of time since, and age at, diagnosis. Cohorts were
simulated using the DMM, and resulting A1c values were com-
pared with DARTS cohorts. Goodness of ﬁt was evaluated by
assessing bias, i.e. the underlying difference between DMM and
DARTS, and stochastic variation. RESULTS: For patients with
T1DM, changes in A1c over time were not predicted well by the
DMM; many of the differences between DARTS and DMM pre-
dicted A1c values were greater than 0.5% and the maximum bias
was 0.9%. For patients with T2DM, the changes were well pre-
dicted for all ages and age bands; maximum bias was 0.5%.
CONCLUSION: The DMM is successful in predicting real world
changes in A1c for T2DM; further work is needed to reproduce
real world changes in A1c for T1DM.
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OBJECTIVES: To evaluate the direction and relative magnitude
of a pharmacogenomics bias resulting from failure to adjust for
genetic heterogeneity in both treatment response (HT) and het-
erogeneity in progression of disease (HP) in decision models
extrapolating beyond short-term trial results. METHODS: We
constructed two Markov models with three health states (early-
stage, late-stage, dead), one adjusting and the other not adjust-
ing for genetic heterogeneity. We compared life expectancy gains
attributable to treatment resulting from both models and deﬁned
pharmacogenomics bias as percent deviation of treatment-
related life expectancy gains in the unadjusted model (UAM)
from those in the adjusted model (AM). We calculated the bias
as a function of underlying model parameters to create generic
results. We then applied our model to lipid-lowering therapy
with pravastatin in patients with coronary atherosclerosis, incor-
porating the inﬂuence of two TaqIB polymorphism variants (B1
and B2) on progression and drug efﬁcacy as reported in the DNA
substudy of the REGRESS trial. RESULTS: Our generic simula-
tion showed that a purely HT-related bias is negative (conserv-
ative) and a purely HP-related bias is positive (liberal). For many
typical scenarios, the absolute bias is smaller than 10%. In case
of joint HP and HT, the overall bias is likely triggered by the HP
component and reaches positive values >100% if fractions of
“fast progressors” and “strong treatment responders” are low.
In the pravastatin example, the UAM overestimated the true life-
years gained (LYG) by 5.5% (1.07 LYG vs. 0.99 LYG for 56-
year-old men). CONCLUSIONS: We have been able to predict
the pharmacogenomics bias jointly caused by heterogeneity in
progression of disease and heterogeneity in treatment response
as a function of characteristics of patients, disease, and treat-
ment. In the case of joint presence of both types of heterogene-
ity, models ignoring this heterogeneity may generate results that
overestimate the treatment beneﬁt.
